Phenotype-Specific Response Patterns to IL-23 Inhibition in Hidradenitis Suppurativa: Pooled Secondary Analysis of Guselkumab and Risankizumab Phase 2 Clinical Trials Journal of the American Academy of Dermatology
Published: 18 August 2026| Version 1 | DOI: 10.17632/ch2r2d4k33.1
Contributor:
Description
Supplementary Data Tables and Methods
Files
Categories
Dermatology, Hidradenitis Suppurativa